Alexion Pharmaceuticals, Inc.  

(Public, NASDAQ:ALXN)   Watch this stock  
Find more results for ALXN
110.87
+0.54 (0.49%)
Nov 17 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 109.61 - 111.27
52 week 96.18 - 149.34
Open 110.15
Vol / Avg. 2.18M/2.24M
Mkt cap 24.77B
P/E 49.56
Div/yield     -
EPS 2.24
Shares 223.41M
Beta 1.22
Inst. own 97%
Feb 14, 2018
Q4 2017 Alexion Pharmaceuticals Inc Earnings Release (Estimated) - 9:30AM EST - Add to calendar
Nov 7, 2017
Alexion Pharmaceuticals Inc at Credit Suisse Healthcare Conference - Webcast
Oct 26, 2017
Q3 2017 Alexion Pharmaceuticals Inc Earnings Call - Webcast
Oct 26, 2017
Q3 2017 Alexion Pharmaceuticals Inc Earnings Release
Sep 27, 2017
Alexion Pharmaceuticals Inc at Leerink Partners Roundtable Series: Rare Disease & Immuno-Oncology - Webcast
Sep 12, 2017
Alexion Pharmaceuticals Inc at Morgan Stanley Healthcare Conference - Webcast
Sep 12, 2017
Alexion Pharmaceuticals Inc to Discuss Restructuring to Advance Corporate Strategy - Conference Call - Webcast
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '17) 2016
Net profit margin 9.08% 12.94%
Operating margin 9.31% 21.63%
EBITD margin - 37.39%
Return on average assets 2.31% 3.03%
Return on average equity 3.51% 4.71%
Employees 3,121 -
CDP Score - -

Address

100 College St
NEW HAVEN, CT 06510-3210
United States - Map
+1-203-2722596 (Phone)
+1-203-2718198 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Alexion Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company's products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company's clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous). Its Soliris is the therapeutic approved for patients with either paroxysmal nocturnal hemoglobinuria (PNH) or hemolytic uremic syndrome (aHUS). PNH and aHUS result from chronic uncontrolled activation of the complement component of the immune system. Its Strensiq is for the treatment of patients with Hypophosphatasia (HPP). Its product, Kanuma is for the treatment of patients with Lysosomal Acid Lipase Deficiency (LAL-D). It is a recombinant form of the human LAL enzyme, which is a replacement therapy that is approved for the treatment for patients with LAL-D.

Officers and directors

David R. Brennan Chairman of the Board
Age: 63
Bio & Compensation  - Reuters
Ludwig N. Hantson Ph.D. Chief Executive Officer, Director
Age: 54
Bio & Compensation  - Reuters
Paul J. Clancy Chief Financial Officer
Age: 55
Bio & Compensation  - Reuters
John B. Moriarty J.D. Executive Vice President, General Counsel
Age: 49
Bio & Compensation  - Reuters
Martin Mackay Ph.D. Executive Vice President, Global Head - Research and Development
Age: 60
Bio & Compensation  - Reuters
Julie O'Neill Executive Vice President - Global Operations
Age: 50
Bio & Compensation  - Reuters
Edward Miller J.D. Senior Vice President, Global Chief Compliance Officer
Age: 52
Bio & Compensation  - Reuters
Heidi L. Wagner J.D. Senior Vice President - Global Governmental Affairs
Age: 52
Bio & Compensation  - Reuters
Brian Goff Chief Commercial Officer
Age: 48
Bio & Compensation  - Reuters
Paul A. Friedman M.D. Director
Age: 74
Bio & Compensation  - Reuters